March 18, 2020 / 10:38 PM / 17 days ago

BRIEF-Roivant Announces Development Of Anti-GM-Csf Monoclonal Antibody To Treat ARDS In Patients With Covid-19

March 18 (Reuters) - ROIVANT:

* ROIVANT ANNOUNCES DEVELOPMENT OF ANTI-GM-CSF MONOCLONAL ANTIBODY TO PREVENT AND TREAT ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) IN PATIENTS WITH COVID-19

* ROIVANT SCIENCES - PHASE 1 STUDY OF GIMSILUMAB CONDUCTED BY ROIVANT COMPLETED DOSING LAST MONTH FOLLOWING EXTENSIVE NON-CLINICAL RESEARCH

* ROIVANT - WILL PRIORITIZE TRIALS OF GIMSILUMAB IN PATIENTS WITH COVID-19 INSTEAD OF A PHASE 2 TRIAL IN A SEPARATE DISEASE AREA Source text for Eikon:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below